BL 5255: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 127678 |
| CHEMBL ID | 14922 |
| SCHEMBL ID | 11625177 |
| MeSH ID | M0077466 |
| Synonym |
|---|
| bl-5255 |
| bl 5255 |
| CHEMBL14922 |
| u6sf3u21bi , |
| unii-u6sf3u21bi |
| 2-(2-n-propoxyphenyl)-5-(5-1h-tetrazolyl)pyrimidin-4(3h)-one |
| 4(1h)-pyrimidinone, 2-(2-propoxyphenyl)-5-(1h-tetrazol-5-yl)- |
| 64634-09-9 |
| NHBDYNVEEOSTIH-UHFFFAOYSA-N |
| 2-(2-n-propoxyphenyl)-5-(5-1h-tetrazolyl) pyrimidin-4(3h)-one |
| SCHEMBL11625177 |
| 5-(1,2-dihydro-5h-tetrazol-5-ylidene)-2-(2-propoxyphenyl)pyrimidin-4(5h)-one |
| DTXSID70983235 |
| 4(3h)-pyrimidinone, 2-(2-propoxyphenyl)-5-(2h-tetrazol-5-yl)- |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID179618 | Antiallergic activity in the passive cutaneous anaphylaxis (PCA) model in the rat was determined after iv administration | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Antiallergy agents. 2. 2-Phenyl-5-(1H-tetrazol-5-yl)pyrimidin-4(3H)-ones. |
| AID179619 | Antiallergic activity in the passive cutaneous anaphylaxis (PCA) model in the rat was determined after oral administration | 1982 | Journal of medicinal chemistry, Oct, Volume: 25, Issue:10 | Antiallergy agents. 2. 2-Phenyl-5-(1H-tetrazol-5-yl)pyrimidin-4(3H)-ones. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||